Andeleeb AL MOBARAQ - DAHY

Andeleeb Al Mobaraq - Dahy has extensive work experience in regulatory affairs, with a focus on the pharmaceutical industry. Andeleeb is currently working at Disc Medicine as the Executive Director Head of Regulatory Affairs. Prior to this, they held the same position at Astellas Pharma Europe and also served as the Senior Director of Global Regulatory Affairs and Global Strategy. In their role at Astellas Pharma Europe, Andeleeb was responsible for regulatory strategy and submission for the development of advanced therapy medicine products, as well as the treatment of rare/orphan diseases with high unmet medical need. Andeleeb also worked on regulatory strategy for precision medicine, including clinical biomarkers and in vitro diagnostics.

Before their time at Astellas Pharma Europe, Andeleeb worked as the Manager of Regulatory Affairs at Sanofi Genzyme. Andeleeb also served as the Registration Manager at Sandoz RCC-EU and as a Project Leader at NVI Dutch Vaccine Institute. Overall, Andeleeb brings over 15 years of experience in regulatory affairs to their current role at Disc Medicine and has a strong background in developing regulatory strategies and submissions for various medical products and treatments.

Andeleeb AL MOBARAQ - DAHY's education history begins in 1991 when they enrolled at Damascus University. Andeleeb studied Pharmacy and Pharmaceutical Chemistry and completed their studies in 1997.

In 2003, they attended Utrecht University for a premaster program in Farmacie. This program lasted for a year.

Between 2004 and 2006, they pursued their Master of Science degree in Farmaceutische wetenschappen - Drug Innovation at Utrecht University.

Overall, Andeleeb AL MOBARAQ - DAHY completed their education in Pharmacy and Pharmaceutical Chemistry at Damascus University and later pursued specialized studies in Drug Innovation at Utrecht University.